Biohaven reported that the FDA accepted its resubmitted new drug application for Vyglxia, or troriluzole, in spinocerebellar ataxia and disclosed a licensing deal with Ono Pharmaceutical for its MoDE ...
Source LinkBiohaven reported that the FDA accepted its resubmitted new drug application for Vyglxia, or troriluzole, in spinocerebellar ataxia and disclosed a licensing deal with Ono Pharmaceutical for its MoDE ...
Source Link
Comments